Background: Glucose degradation products (GDPs) in peritoneal dialysis (PD) solution (PDS) have been shown to inflict damage to the kidney, which is the major organ for advanced glycosylation end product elimination. Hence, this study investigated whether new PDSs with neutral pH and low-GDPs have a beneficial effect on the preservation of residual renal function (RRF) among PD patients. Methods: Randomized controlled trials examining the effect of neutral pH and low-GDP PDSs on RRF in PD patients >18 years old compared with conventional PDSs were selected. The modality of PD treatment was continuous ambulatory PD. The primary outcome variable was mean RRF value. Weekly Kt/V, urine volume, peritoneal ultrafiltration, blood pressure and all-cause mortality of PD patients were measured as secondary outcome variables. Results: We identified 6 randomized controlled trials and found that patients using low-GDP PDSs had a much slower rate of RRF loss compared with patients using conventional PDSs [mean difference (MD) = 0.45, 95% confidence intervals (CI) 0.10-0.80, p = 0.01]. In addition, weekly Kt/V was markedly improved in the low-GDP PDS group (MD = 0.13, 95% CI 0.06-0.21, p = 0.0005), and urine volume was increased (MD = 110.34, 95% CI 8.58-212.10, p = 0.03). No significant differences were observed between the two groups with respect to peritoneal ultrafiltration, blood pressure and risk of all-cause mortality. Conclusion: Our meta-analysis demonstrates a significant benefit of using low-GDP PDSs for RRF preservation in PD patients. Further trials are needed to determine whether this beneficial effect can affect long-term clinical outcomes.

Keywords:
Glucose degradation products, Peritoneal dialysis solution, Residual renal function, Peritoneal dialysis, Meta-analysis
1.
Krediet RT: 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 2007;27(suppl 2):S35-S41.
2.
Lameire N, Van BW: Epidemiology of peritoneal dialysis: a story of believers and nonbelievers. Nat Rev Nephrol 2010;6:75-82.
3.
Bargman JM, Thorpe KE, Churchill DN, et al: CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-2162.
4.
Rumpsfeld M, McDonald SP, Johnson DW: Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2009;29:637-646.
5.
Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-2162.
6.
Termorshuizen F, Korevaar JC, Dekker FW, et al: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003;41:1293-1302.
7.
Wang A: The ‘heart' of peritoneal dialysis: residual renal function. Perit Dial Int 2007;27:116-124.
8.
Millar DJ, Holmes C, Faict D, et al: Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998;14:191-194.
9.
Justo P, Sanz AB, Egido J, et al: 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005;54:2424-2429.
10.
Szeto CC, Chow KM, Lam CW, et al: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products: a 1-year randomized control trial. Nephrol Dial Transplant 2007;22:552-559.
11.
Fan SL, Pile T, Punzalan S, et al: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008;73:200-206.
12.
Higgins JPT, Green S, eds: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.6. The Cochrane Collaboration, 2012. www.cochrane-handbook.org.
13.
Kim YL, Do JY, Park SH, et al: Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology 2003;8:S28-S32.
14.
Le Poole, Welten AG, Weijmer MC, et al: Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids is safe and efficacious. Perit Dial Int 2005;25(suppl 3):S64-S68.
15.
Kim S, Oh J, Kim S, et al: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009;24:2899-2908.
16.
Johnson DW, Brown FG, Clarke M, et al: Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012;23:1-11.
17.
Park Sh, Do JY, Kim YH, et al: Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Nephrol Dial Transplant 2012;27:1191-1199.
18.
Mujais S, Nolph K, Gokal R, et al: International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis: Evaluation and management of ultrafiltration problems in peritoneal dialysis. Perit Dial Int 2000;20(suppl 4):S5-S21.
19.
Piraino B, Bernardini J, Brown E, et al: ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011;31:614-630.
20.
Zeier M, Schwenger V, Deppisch R, et al: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
21.
Badve SV, Hawley CM, McDonald SP, et al: Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant 2012;27:381-387.
22.
Shemin D, Maaz D, St Pierre D, et al: Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999;34:14-20.
23.
Montenegro J, Saracho R, Gallardo I, et al: Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007;22:1703-1708.
24.
Furket J, Zeier M, Schwenger V: Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 2008;28:637-640.
25.
Haag-Weber M, Kramer R, Haake R, et al: Low-GDP fluid attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010;25:2288-2296.
26.
Choi HY, Kim DK, Lee TH, et al: The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008;28:174-182.
27.
Lee HY, Park HC, Seo BJ, et al: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration. Perit Dial Int 2005;25:248-255.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.